Prothrombin (factor II) is one of the phospholipid binding proteins with a procoagulant property.
Some publications have shown the presence of autoantibodies against prothrombin (aPT) in patients with antiphospholipid antibodies (aPL).
We assessed the clinical significance of aPT in thrombotic events in patients with systemic lupus erythematosus (SLE).
IgG and IgM aPT were tested by ELISA in 207 patients with SLE.
Fifty-eight patients (28%) had positive aPT (>mean+3 SD of 100 controls).
Twenty-eight (14%) had IgG alone, 21 (10%) IgM alone, and 9 (4%) had both IgG and IgM.
Patients with aPT had a history of thrombosis more frequently than those without aPT [31/58 (53%) vs 47/149 (32%), chi-squared=7.6. p=0.006]. No correlation was found between the presence of aPT and clinical features of SLE.
APT are frequently found in patients with SLE, and are a potential marker for thrombosis.
Mots-clés Pascal : Lupus érythémateux, Disséminé, Association, Antiphospholipide syndrome, Anticorps, Autoanticorps, Epidémiologie, Symptomatologie, Prévalence, Thrombose, Technique ELISA, Homme, Thrombocyte, Peau pathologie, Tissu conjonctif pathologie, Maladie système, Maladie autoimmune, Immunopathologie, Appareil circulatoire pathologie, Vaisseau sanguin pathologie, Hémopathie
Mots-clés Pascal anglais : Lupus erythematosus, Disseminated, Association, Antiphospholipid antibody syndrome, Antibody, Autoantibody, Epidemiology, Symptomatology, Prevalence, Thrombosis, ELISA assay, Human, Platelet, Skin disease, Connective tissue disease, Systemic disease, Autoimmune disease, Immunopathology, Cardiovascular disease, Vascular disease, Hemopathy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0311404
Code Inist : 002B07. Création : 27/11/1998.